Non classé

Rising Tide Foundation for Clinical Cancer Research: Empowering Patient-Centred Innovations

The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is a non-profit, charitable organisation founded in 2010 in Schaffhausen, Switzerl...

Read

EU Roundtable Calls for Urgent Action on Disease-Related Malnutrition in Cancer Care

Brussels, February 5, 2025 – The European Parliament recently hosted a crucial roundtable discussion on “Advancing Optimal Nutritional Care: Ad...

Read

DiCE Advocates for Awareness at PANCAID Stakeholder Event

On 15 January 2025, DiCE actively participated in the PANCAID Stakeholder Event at the European Parliament in Brussels, organised by Pancreatic Can...

Read

IMPROVE-2 Trial: A New Treatment Approach for mCRC

The IMPROVE-2 trial is exploring a new way to treat metastatic colorectal cancer (mCRC) by comparing intermittent versus continuous use of Panitumu...

Read

READI Project Officially Launched: Pioneering Diversity and Inclusion in Clinical Studies

On January 16, 2025, the groundbreaking READI project—Research in Europe and Diversity Inclusion—officially launched. Funded by the Horizon Eur...

Read

ESMO Expands Globally with New Patient Advocates Working Group

ESMO is proud to announce the launch of its newly globalised Patient Advocates Working Group (PAWG), now led by Zorana Maravic as Chair. This miles...

Read

Empowering Cancer Patients: SmartCARE Showcase Event

The SmartCARE Showcase Event, organised by the European Cancer Organisation, brought together patient advocates, clinicians, and IT experts to intr...

Read

Advancing Rare Cancer Care: DiCE at the EURACAN Board Meeting

On the 7th and the 8th of November, Laura Urena from Digestive Cancers Europe (DiCE) and a member of EURACAN Patient Advocacy Group (EPAG), partici...

Read

United Against Cancer: Driving Policy and Advocacy at the European Cancer Summit 2024

This event explored innovative strategies to address inequalities and advance cancer care across Europe, aligning closely with Digestive Cancers Eu...

Read

Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer

Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...

Read

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.